



Dr Henning Gädeke, Chair of the Global Health EDCTP3 Joint Undertaking Governing Board
c/o Dr Michael Makanga, Executive Director Global Health EDCTP3 Joint Undertaking Executive Director
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d’Or
1060 Brussels
Belgium

1 September 2025

Letter of endorsement

Dear Sir/Madam,

On behalf of STICHTING TUBERCULOSIS VACCINE INITIATIVE (TBVI), Runderweg 6, 8219 PK, Lelystad, The Netherlands, VAT number: NL8191.22.452.B.01 and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

TBVI is a non-profit foundation based in Lelystad, The Netherlands. TBVI has extensive experience in coordinating and managing EU- and EDCTP-funded projects on TB vaccine development, including large and complex international and multidisciplinary consortia. TBVI’s strategy is to support both efforts to accelerate clinical development and efforts to design and develop new vaccine concepts in order to diversify the vaccine development pipeline. Both will be critical to ensure future implementation of safe, efficacious, and affordable vaccines to prevent and stop TB worldwide. TBVI’s strategic directions align well with the two main objectives of Global Health EDCTP3 JU (1) to reduce the socio-economic burden of infectious diseases in sub-Saharan Africa by promoting the development and uptake of new or improved health technologies and (2) to increase health security in sub-Saharan Africa and globally by strengthening research capacities for preparedness and response to control infectious diseases.

Together with its strategic partner, European Vaccine Initiative (EVI), TBVI intends to support the ACTTIVAC proposal (Final ID: 101248955-2), that has been submitted in response to call HORIZON-JU-GH-EDCTP3-2025-01-TB-01-two-stage (Global collaboration action for the development of vaccines for reducing the disease burden of Tuberculosis in sub-Saharan Africa), via an IKOP contribution. More specifically, this IKOP contribution (€ 25,000) will be used to complement requested funding (€ 50,000) for the organization of two 3-day vaccinology workshops that will be organized in sub-Saharan Africa. Each workshop will host around 30 early-career scientists from sub-Saharan Africa and focus on vaccinology, TB vaccine product development, regulatory requirements, and practical case studies using TBVI’s TB Vaccine Development Pathway (<https://www.tbvacpathway.org/>). Importantly, the workshops will also provide a networking platform across EDCTP3-funded TB vaccine projects, via the intended IKOP co-funding by EVI.

Our IKOP contribution will specifically support Task 6.6 (Vaccinology and Product Development Workshops) in the ACTTIVAC proposal. This task is part of WP6 that is dedicated to the Development of Clinical Research Capacity. Results obtained within task 6.6 will be reported as part of deliverable D6.5 (Final Training Outcomes

Report), due at month 36. The IKOP contribution will be used for salary of seconded staff for preparing the workshops, travel for instructors and course participants to the workshop, and cost of venue for the workshop.

We estimate the total value of this contribution to be EUR 25,000. Will we organize two workshops in sub-Saharan Africa, one in Southern Africa and another in a TB high-burden country in West Africa . The workshops are tentatively planned for year 2 and 3 of the project

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,



Dr Ole Olesen
Executive Director TBVI
ole.olesen@tbvi.eu